BRCA2 and breast cancer: This is particularly relevant to BRCA 1/2 mutation carriers who confer a higher risk of breast cancer themselves, and are offered tamoxifen as chemoprophylaxis or treatment for breast cancer, particularly in BRCA2 carriers.